Issue 02: Antivenom

The Wild Type is a weekly look at the most interesting thing happening in biotech, written for the curious rather than the credentialed. I am Riya, a biology student, and each issue is one idea, explained properly, in about five minutes. No background required.

This week: the man whose blood might beat snakebite, and why curing it ever came down to him.

Earlier this year the same man kept surfacing in my feed: Tim Friede, a truck mechanic from Wisconsin. Beginning in 2000, he spent eighteen years injecting himself with snake venom around 650 times and letting his own snakes bite him about 200 more, on purpose. In September 2001 two cobras bit him within an hour and he woke from a four-day coma. He kept going. In May 2025 that habit turned into a paper in the journal Cell: antibodies drawn from his blood, combined into a single cocktail, protected mice against the venom of 13 of the 19 deadliest snakes tested.

The headlines wrote themselves: the man who survived 200 bites and became the cure. It is a good story, and mostly true. What nagged at me was the question underneath it. Why did a universal antivenom come down to one man's arm at all? The science is clever. Why it was needed is a different story.

The scale is the part most people get wrong. Every year snakes cause around 2.7 million envenomings and kill between 81,000 and 138,000 people, with roughly three times that many left with amputations or lasting disability. Even the low end of that range outnumbers the people dengue kills in a year, a disease with far more funding and headlines. About 95% of the deaths fall on poor rural communities across sub-Saharan Africa and South and Southeast Asia. India alone loses about 58,000 people a year, close to half the world's total. And for years the problem was treated as a footnote: WHO listed snakebite as a neglected tropical disease in 2009, dropped it in 2013, and only restored it as a priority in 2017. The dying held steady the whole time.

Here is what reframes the Friede story. Antivenom has barely changed since Albert Calmette built the first one in the 1890s: you milk a snake by hand, inject the venom into a large animal, almost always a horse, because a body that big makes antibodies by the liter and can survive doses that would kill a person, then harvest the antibodies from its blood. It works, but it is tied to the animal and the region, needs refrigeration, and can trigger dangerous allergic reactions because it is built from horse protein. It also only helps if you reach a clinic that stocks it, which is why an estimated 75% of snakebite deaths happen before the victim reaches a hospital.

None of that is the part that gets me. We once had good antivenom and walked away from it. Fav-Afrique, made by Sanofi and effective against ten of the region's deadliest snakes, was the most trusted product for sub-Saharan Africa. Sanofi decided in 2010 to stop, and the last batch expired in 2016. The reason had nothing to do with the science. Cheaper competitors had eaten into sales and the market was no longer worth the trouble. A dose ran north of $100, so demand looked small even as people died, and cheaper products flooded in, many raised against the wrong snakes. The recipe was not lost, though: Sanofi handed its antivenom line to a Welsh company, MicroPharm, which with Wellcome funding is still working to relaunch it, and it has not been made since 2014. Other pan-African antivenoms exist, but a 2019 review of sixteen found most had weak evidence or signs they did not work. So the problem was never that nobody could solve it. People solved it decades ago. The market collapsed, the manufacturing followed, and the fix is still stuck in the slow work of restarting the line.

Which brings us back to Friede. His idea was to do to his own body what antivenom makers do to horses. "I became the horse," he told Science. The company that saw the worth in it is Centivax, run by immunologist Jacob Glanville, who found Friede through his old YouTube videos and realized that eighteen years of self-exposure had trained one human immune system against a wide range of the world's deadliest venoms, something no ethics board would ever approve. Friede is now the company's director of herpetology.

The approach matters because it drops the animal. Glanville's team pulled antibodies from Friede's memory B cells and screened more than a billion of them for the few that neutralize toxins shared across elapid snakes. One, LNX-D09, protected mice against six species on its own. Adding varespladib, a small molecule that blocks a common venom enzyme, brought in three more. A second antibody, SNX-B03, extended coverage across all 19: full survival for 13 species, partial for the rest. Because the antibodies come from a person rather than a horse, they should avoid much of the allergic risk.

Now the part the triumphant write-ups skip. Those 19 snakes are all elapids, the cobras and mambas and kraits, and the cocktail does nothing against vipers, which cause a huge share of the damage, Russell's viper in India among them. It has been tested only in mice, with no human trials yet, and Andreas Laustsen-Kiel, a toxinologist at the Technical University of Denmark, called the self-immunization "bad practice" and the result a proof of principle. It is a real advance, and a long way from a vial on a shelf in Bihar.

Friede spent eighteen years running an experiment on himself that no lab could, for a disease the industry had already left behind. I find that moving, and a little damning, for what it says about everyone who was better placed to act. The chemistry was settled in the 1890s, and the upgrades that would make it cheaper and safer, human antibodies and a pill you can carry, are already in trials. What keeps going missing has never been the science, only the will to make a medicine for people who will never add up to a lucrative market.

Which is what makes his blood such an unlikely piece of good news. The problem yields to almost anyone willing to take it seriously, up to and including a truck mechanic who taught himself immunology from a textbook and kept his cobras in the basement. The question now is whether the people with real factories decide to take it as seriously as he did, or whether snakebite slips back into the quiet once the headlines move on.